Attendees at Diabetes: Secondary Complications, Regulation and Innovation, will hear Timothy Broke-Smith, Chief Operating Officer from Diabetology provide delegates with a unique insight into the oral delivery of insulin and other diabetes therapies. The address covered in the Clinical Development and Innovation session will draw from Axcess™ and Capsulin™ case study examples as well as discussing oral GLP-1.

Joining Diabetology at the 11th installment in the Diabetes series will be Glaxo SmithKline, Novo Nordisk, Celaris Biosystems, The International Diabetes Federation, Imperial College London and AstraZeneca.

THE CONFERENCE AIMS TO:

  • Consider microvascular complications of diabetes in a round table discussion led by Sanofi, MSD, Four New Square, Medicines Assessment and Imperial College London.
  • Utilise biomarkers and imaging for the development of novel therapies for diabetes
  • Discuss new therapeutic targets to reduce hypertension, hyperkalaemia and endothelial inflammation in diabetes
  • Examine new EU and FDA guidelines on clinical trials on risk-benefit assessment
  • Capitalise on the effects of targeting RAAS, CCN2 and CCN3 inhibitors
  • Review clinical results from the DEMAND study
  • Provide attendees with clinical updates on novel GLP1 receptor agonists, and SLGT2 and DPP-4 inhibitors

Diabetes - 1st and 2nd October, 2013, London UK

For further details visit www.smi-online.co.uk/goto/2013diabetes-conference54.asp

About SMi Group

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. We hold events in over 30 major cities throughout the world including London, Paris and Singapore and to date have welcomed over 200,000 participants from 80 countries.